These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 6507379)

  • 1. Monitoring clinical research. A report from the Childrens Cancer Study Group.
    Stowe SM; Hammond GD; Chard R; Hornberger JA; Honour RC; Sposto R; Weiner JM
    Am J Clin Oncol; 1984 Oct; 7(5):557-66. PubMed ID: 6507379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The scientific basis of clinical trials: statistical aspects.
    Gehan EA
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2587-90. PubMed ID: 9815661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experience.
    Buchanan DR; White JD; O'Mara AM; Kelaghan JW; Smith WB; Minasian LM
    J Clin Oncol; 2005 Sep; 23(27):6682-9. PubMed ID: 16170176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethical communication in clinical trials. Issues faced by data managers in obtaining informed consent.
    Loh WY; Butow PN; Brown RF; Boyle F
    Cancer; 2002 Dec; 95(11):2414-21. PubMed ID: 12436450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The analysis of physicians' work: announcing the end of attempts at in vitro fertilization].
    Santiago-Delefosse M; Cahen F; Coeffin-Driol C
    Encephale; 2003; 29(4 Pt 1):293-305. PubMed ID: 14615699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites.
    Zon R; Meropol NJ; Catalano RB; Schilsky RL
    J Clin Oncol; 2008 May; 26(15):2562-7. PubMed ID: 18390967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experiences in the realisation of a research project on anthroposophical medicine in patients with advanced cancer.
    von Rohr E; Pampallona S; van Wegberg B; Hürny C; Bernhard J; Heusser P; Cerny T
    Schweiz Med Wochenschr; 2000 Aug; 130(34):1173-84. PubMed ID: 11013920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Policies for clinical trials in cancer].
    Suemasu K
    Gan No Rinsho; 1988 Jan; 34(1):7-12. PubMed ID: 3339851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maybe more is better.
    Thigpen T
    J Clin Oncol; 2003 Jul; 21(13):2454-6. PubMed ID: 12829661
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical trials for gynecological cancers (especially ovarian cancers) in Japan, current situation and problems--focusing on differences in the system of study used by Japanese Study Group and the Gynecologic Oncology Group in the United States].
    Fujiwara K; Kohno I
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():395-401. PubMed ID: 7986120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adapting clinical trials networks to promote cancer prevention and control research.
    Weiner BJ; McKinney MM; Carpenter WR
    Cancer; 2006 Jan; 106(1):180-7. PubMed ID: 16333855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Quality control in clinical trials].
    Fukushima M
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):172-82. PubMed ID: 8611045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.